There's a lot to like about the Core NK platform - the primary differentiator (for me) is the simplicity of the platform technology. It is based on the non-engineering of Natural Killer immune cells and simply the expansion of population numbers. Multiple patients can be treated from off-the-shelf NK cells from a single donor. Unlike T cells, NK cells are less likely to cause graf-versus-host disease (GVHD).
Similar NK platforms have been swooped upon by big players such as Merck and Kite. From what I can gather (from the above pdf and by the patent application) what's different from other NK cell platforms is that our particular feeder cell line (the basis of the technology) results in superior expansion levels.
The simplicity and effectiveness of Core NK (thus far) make it a great candidate for combo therapy. Our platform can be readily turned into Car-NK products but not only that, it is now in the clinic under MD Anderson's investigation in combo with, not one but two, front-line (commercialised) drugs. As you rightly point out, Steini... our current trial in AML in partnership with MDA speaks volumes to the commercial potential here.
MDA is referenced in the above PDF (published in 2019 and featured on our website). If my understanding serves me correctly from a brief read, the reference is in the context of previous feeder cell lines adopted by others. So, it could be quite significant that MDA is collaborating with CHM and using our platform in a trial at their Cancer Centre in Texas.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)